NCT01989221View on ClinicalTrials.gov

Sancuso® for Gastroparesis: An Open Label Study.

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Gastroparesis
Interventions
DRUG

Sancuso®

Sancuso® (granisetron transdermal system) 3.1 mg/24 hours

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

All Listed Sponsors
lead

Temple University

OTHER

NCT01989221 - Sancuso® for Gastroparesis: An Open Label Study. | Biotech Hunter | Biotech Hunter